TVM Capital Life Science leads Series C investment round for CoLucid Pharmaceuticals

1 minute read
01 January 2015

On January 13, 2015, CoLucid Pharmaceuticals, Inc., announced that it had completed a $37.1 million Series C preferred stock offering. The financing was led by TVM Capital Life Science, based in Montreal and Munich, and included participation from new investors Novo Ventures and Auriga Partners. CoLucid’s existing investors also participated.

CoLucid is developing oral lasmiditan for the acute treatment of migraine headache and intravenous lasmiditan for treatment of headache pain by health care professionals.

TVM Capital Life Science provides venture capital to the international pharmaceutical, biopharmaceutical and medical technology industries with in excess of US$1.3 billion under management.

Gowlings advised TVM with respect to this investment with a team that included Vanessa Grant and Matthew Literovich.

NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.